Department of Hygiene, Epidemiology and Medical Statistics Medical School, National and Kapodistrian University of Athens, Athens Greece.
Department of Pediatric Hematology-Oncology, "Pan. & Agl. Kyriakou" Children's Hospital, Athens, Greece.
Eur J Cancer. 2018 Jun;96:44-53. doi: 10.1016/j.ejca.2018.03.003. Epub 2018 Apr 16.
Neuroblastoma outcomes vary with disease characteristics, healthcare delivery and socio-economic indicators. We assessed survival patterns and prognostic factors for patients with neuroblastoma in 11 Southern and Eastern European (SEE) countries versus those in the US, including-for the first time-the Nationwide Registry for Childhood Hematological Malignancies and Solid Tumours (NARECHEM-ST)/Greece.
Overall survival (OS) was calculated in 13 collaborating SEE childhood cancer registries (1829 cases, ∼1990-2016) and Surveillance, Epidemiology, and End Results (SEER), US (3072 cases, 1990-2012); Kaplan-Meier curves were used along with multivariable Cox regression models assessing the effect of age, gender, primary tumour site, histology, Human Development Index (HDI) and place of residence (urban/rural) on survival.
The 5-year OS rates varied widely among the SEE countries (Ukraine: 45%, Poland: 81%) with the overall SEE rate (59%) being significantly lower than in SEER (77%; p < 0.001). In the common registration period within SEE (2000-2008), no temporal trend was noted as opposed to a significant increase in SEER. Age >12 months (hazard ratio [HR]: 2.8-4.7 in subsequent age groups), male gender (HR: 1.1), residence in rural areas (HR: 1.3), living in high (HR: 2.2) or medium (HR: 2.4) HDI countries and specific primary tumour location were associated with worse outcome; conversely, ganglioneuroblastoma subtype (HR: 0.28) was associated with higher survival rate.
Allowing for the disease profile, children with neuroblastoma in SEE, especially those in rural areas and lower HDI countries, fare worse than patients in the US, mainly during the early years after diagnosis; this may be attributed to presumably modifiable socio-economic and healthcare system performance differentials warranting further research.
神经母细胞瘤的结局因疾病特征、医疗保健提供和社会经济指标而异。我们评估了 11 个东南欧(SEE)国家和美国的神经母细胞瘤患者的生存模式和预后因素,其中包括首次纳入了希腊全国儿童血液恶性肿瘤和实体瘤登记处(NARECHEM-ST)的数据。
计算了 13 个合作 SEE 儿童癌症登记处(1829 例病例,约 1990-2016 年)和美国监测、流行病学和最终结果(SEER)(3072 例病例,1990-2012 年)的总生存(OS)。使用 Kaplan-Meier 曲线和多变量 Cox 回归模型,评估年龄、性别、原发肿瘤部位、组织学、人类发展指数(HDI)和居住地(城市/农村)对生存的影响。
SEE 国家之间的 5 年 OS 率差异很大(乌克兰:45%,波兰:81%),总体 SEE 率(59%)显著低于 SEER(77%;p<0.001)。在 SEE 内的共同登记期间(2000-2008 年),没有观察到时间趋势,而 SEER 则明显增加。12 个月以上年龄(后续年龄组的危险比[HR]:2.8-4.7)、男性(HR:1.1)、农村地区居住(HR:1.3)、居住在高(HR:2.2)或中(HR:2.4)HDI 国家和特定的原发肿瘤部位与预后不良相关;相反,神经节神经母细胞瘤亚型(HR:0.28)与较高的生存率相关。
考虑到疾病特征,SEE 中的神经母细胞瘤患儿,尤其是农村地区和 HDI 较低国家的患儿,比美国的患儿预后更差,主要是在诊断后早期;这可能归因于可归因于可改变的社会经济和医疗保健系统表现差异,需要进一步研究。